Minireviews
Copyright ©The Author(s) 2018.
World J Gastroenterol. Jul 7, 2018; 24(25): 2686-2697
Published online Jul 7, 2018. doi: 10.3748/wjg.v24.i25.2686
Table 2 Phase II and III clinical trials of programmed cell death 1 inhibitors in advanced gastroesophageal cancer
n (phase)Experimental armControl or reference armPrimary endpointResultsRef.
160 (I/II)N1 + I3: Nivolumab 1 mg/kg every 2 wk and ipilimumab 3 mg/kg every 3 wkN3: Nivolumab 3 mg/kg every 2 wkORRN3: ORR 12%, PD-L1 ≥ 1% ORR 19%, PD-L1< 1% ORR 12%CheckMate 032 [54]
N3 + I1: Nivolumab 3 mg/kg and ipilimumab 1 mg/kg every 3 wkN1+I3: ORR 24%, PD-L1≥ 1% ORR 40%, PD-L1< 1% ORR 22%
Gastric, esophageal, or GEJ cancerN3+I1: ORR 8%, PD-L1 ≥ 1% ORR 23%, PD-L1 < 1% ORR 0%
259 (II)Cohort 1 (after ≥ 2 lines of therapy): Pembrolizumab 200 mg every 3 wk up to 2 yr, PD, decision to withdraw, or unacceptable toxicity in gastric cancerN/AORR, safety, tolerabilityOverall ORR 11.2% (95%CI: 7.6-15.7), CR 1.9% (95%CI: 0.6-4.4), PR 9.3% (95%CI: 6.0-13.5), SD 17% (95%CI: 12.6-22.1), PD 55.6% (95% CI 49.3-61.7)KEYNOTE 059 [56]
PD-L1+ ORR 15.5% (95% CI 10.1-22.4), PD-L1- ORR 5.5% (95% CI 2.0-11.6)
25 (II)Cohort 2 (1st line): pembrolizumab 200 mg every 3 wk for up to 2 yr, cisplatin (80 mg/m2 day 1), and 5-FU (800 mg/m2 D1-5 Q3W) or capecitabine (1000 mg/ m2 bid)N/ASafety, ORRCohort 2: ORR 60% (39-79) overall, 73% (45-92) PD-L1+, 38% (9-76) PD-L1-. Median PFS 7 moKEYNOTE 059 [55]
31 (II)Cohort 3 (PD-L1+, 1st line): pembrolizumab 200 mg every 3 wk for up to 2 yrN/ASafety, ORRCohort 3: ORR 26% (12-45). Median PFS 3 moKEYNOTE 059 [55]
Gastric or GEJ cancer
41 (II)Pembrolizumab 10 mg/kg every 2 wkCohort B: MMR-proficient CRCORR, PFSMMR-deficient CRC: ORR 40%, PFS 78%; median PFS and OS not reachedKeynote-016 [58]
Cohort A: Mismatch repair (MMR)-deficient colorectal cancers (CRC)MMR-proficient CRC: ORR 0%, PFS 11%; median PFS 2.2 mo, OS 5.0 mo
Cohort C: MMR-deficient non-CRCMMR-deficient non-CRC: ORR 71%, PFS 67%
86 (II)Pembrolizumab 10 mg/kg every 2 wk for MMR-deficient cancers (12 tumor types)N/AORR, PFSObjective radiographic response 53%, CR 21%; median PFS and OS not reached[59]
493 (III)Nivolumab 3 mg/kg every 2 wk until unacceptable toxicity or PD in gastric/GEJ cancersPlaceboOSNivolumab: median OS 5.32 mo, 6-mo OS 46.4%, 12-mo OS 26.6%, ORR 11.2%, median PFS 1.61 moATTRACTION-02 [57]
Placebo: median OS 4.14 mo, 6-mo OS 34.7%, 12-mo OS 10.9%, ORR 0%, median PFS 1.45 mo